Pharma BD Deal Intelligence
GlaxoSmithKline plc / Concert Pharmaceuticals, Inc.
2009 · Licensing/Option · $35M · Complete
Announcement Sentiment
79
Strongly positive
Strategic alliance for deuterium-modified medicines: $35M upfront incl. $16.7M equity; CTP-518 (HIV PI), preclinical CKD compound, 3rd program. Source: GSK press, Concert filings.
Key facts
- Announced Mar 30, 2009
- Deal value $35M
- Deal type Licensing/Option
See the full interactive analysis, sources & comparables →
← Browse all deals ·
How we score deals